Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

322
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
322
Lower GI Series: Barium Enema01:23

Lower GI Series: Barium Enema

1.1K
A Barium Enema, or a lower GI series, is a specialized radiographic examination designed to visualize the lower gastrointestinal tract, specifically the colon and rectum. This procedure is instrumental in diagnosing various conditions such as colorectal cancer, polyps, diverticulosis, and inflammatory bowel disease.
Procedure Details
The examination begins by inserting a lubricated rectal tube into the patient's rectum to administer a radiopaque barium solution. The barium flow is carefully...
1.1K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

488
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
488
Assessment of the Gastrointestinal System I: Subjective Data01:17

Assessment of the Gastrointestinal System I: Subjective Data

566
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
566
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

689
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
689
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.1K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute upper gastrointestinal bleeding: a population-based cohort study from Southern Iceland.

Scandinavian journal of gastroenterology·2026
Same author

HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

An update on drug-induced liver injury-What's new?

Journal of internal medicine·2026
Same author

Exploring the influence of sex on <i>idiosyncratic</i> DILI: impact on risk assessment.

Expert opinion on drug metabolism & toxicology·2026
Same author

Editorial: The Role of Liver Biopsy in ANA Positive Subjects.

Alimentary pharmacology & therapeutics·2026
Same author

Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.

EBioMedicine·2026

Related Experiment Videos

Acute lower gastrointestinal bleeding: A population-based five-year follow-up study.

Johann P Hreinsson1, Silja Ægisdottir2, Einar S Bjornsson1,2

  • 1Department of Internal Medicine, Section of Gastroenterology and Hepatology, The National University Hospital, Reykjavik, Iceland.

United European Gastroenterology Journal
|December 17, 2019
PubMed
Summary

Acute lower gastrointestinal bleeding (ALGIB) affects 14% of patients undergoing endoscopy. Age and inflammatory bowel disease (IBD) predict rebleeding, but ALGIB does not impact long-term survival.

Keywords:
GI bleeding outcomeGI bleeding prognosisGI rebleeding risk factorsGastrointestinal haemorrhagenatural history of GI bleeding

Related Experiment Videos

Area of Science:

  • Gastroenterology
  • Clinical Medicine
  • Epidemiology

Background:

  • Limited data exists on the natural history of acute lower gastrointestinal bleeding (ALGIB).
  • Understanding long-term bleeding risk and mortality in ALGIB patients is crucial.
  • Identifying predictors of rebleeding is essential for patient management.

Purpose of the Study:

  • To evaluate the five-year bleeding risk and mortality in patients with ALGIB compared to controls.
  • To identify predictors of rebleeding in patients who experienced ALGIB.

Main Methods:

  • A population-based, retrospective case-control study was conducted.
  • Patients undergoing endoscopy between 2010-2011 were included, with ALGIB defined as significant rectal bleeding.
  • Controls without gastrointestinal bleeding (GIB) were matched for age and sex, with a five-year follow-up.

Main Results:

  • 14% of 2294 patients had ALGIB; the five-year rebleeding risk was 20% versus 3% in controls.
  • Age (OR 1.3 per decade) and inflammatory bowel disease (IBD) (OR 4.3) were predictors of rebleeding.
  • ALGIB patients did not show a higher five-year mortality risk compared to controls (HR 1.2).

Conclusions:

  • Approximately one-fifth of ALGIB patients experienced rebleeding within five years.
  • Age and IBD are independent predictors for rebleeding after ALGIB.
  • Acute lower gastrointestinal bleeding does not appear to be associated with reduced long-term survival.